News

About 500 patients will be enrolled in the randomized, double-blind, placebo-controlled phase 3 study, dubbed Cascade, which will assess 33A in combination with azacitidine (Vidaza) or decitabine (Dacogen)

The 15-member panel of the Endocrinologic and Metabolic Drugs Advisory Committee voted 12 to 2 (1 panelist did not vote due to travel) to approve the combination. Two

ALKS 4230, which was formerly referred to as RDB 1450, a novel selective effector cell activator protein designed to preferentially bind and signal through the intermediate affinity interleukin-2

The study, conducted in partnership with Amplion and Biomedtracker, recorded and analyzed 9,985 clinical and regulatory phase transitions, across 1,103 companies. Using clinical trial data from the past

The lead, a reversible BTK inhibitor, offers exciting potential to treat Chronic Lymphocytic Leukaemia (CLL) patients who have become resistant to the gold standard therapy, Imbruvica (ibrutinib). This

IDegLira is a once-daily, single injection fixed combination of insulin degludec (Tresiba) and liraglutide (Victoza) for the treatment of adults with type 2 diabetes. Based on the data

In addition, Lilly could launch an average of two new indications or line extensions for already-approved products per year during that same time period. "We’re pleased to share

Headline results from the 2,802-patient Salford Lung Study (SLS) in COPD showed that the inhaled therapy achieved a superior reduction in exacerbations versus usual care – which included

A total 115 patients were enrolled in the placebo-controlled, randomized, double-blind trial, which evaluated the efficacy and safety of three separate, twice-daily, dosing regimens of Prurisol — 50